VERZENIOTM (abemaciclib) Approved for Treatment of Metastatic Breast...

VERZENIOTM (abemaciclib) Approved for Treatment of Metastatic Breast...


Biologics, Inc. , a McKesson Specialty Health oncology pharmacy services company, has been selected by Eli Lilly and Company to be in the limited distribution network for VERZENIOTM , Eli Lilly's first oral oncolytic indicated for metastatic breast cancer. Approved by the U.S. Food and Drug Administration on September 28, 2017, VERZENIO is a CDK inhibitor selective for CDK4 and CDK6.



from Biotech News
Share:

Комментариев нет:

Отправить комментарий

Pharmacy News Digest

Архив блога